HLB
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
HLB is a South Korean conglomerate listed on KOSDAQ that operates across healthcare, biopharmaceuticals, and marine engineering.
Its healthcare arm supplies diagnostic test kits, blood-glucose monitoring devices, antiseptic products, and medical consumables to domestic and international pharmaceutical and diagnostics companies. Its biopharma subsidiaries are developing targeted cancer therapies, including an oral treatment for liver cancer and a licensed drug candidate for bile-duct cancer. Its marine division designs and builds specialised vessels, lifeboats, and composite piping systems for government agencies, coast guards, and shipyards.
Summary is AI-generated and may contain errors · figures from DART filings
HLB operates through distinct subsidiaries including Elevar Therapeutics and Immunomic Therapeutics on the biopharma side, giving it a multi-entity structure spanning Korea and overseas.
HLB in five facts
What does HLB do?
HLB is a South Korean conglomerate listed on KOSDAQ that operates across healthcare, biopharmaceuticals, and marine engineering.
Where is HLB listed and in which sector?
HLB (Korean name: HLB) trades under KRX code 028300 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is HLB?
Its market capitalisation was US$4.3B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were HLB's latest annual revenue and operating profit?
For fiscal year 2025, HLB reported revenue of US$63.5M, an operating loss of US$78.7M and a net loss of US$177.7M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 23.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Conversion price adjustmentOct 15
- Investor relations (IR) meetingOct 12
- DisclosureOct 12
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Sep 8
- Report on large shareholdings (5% rule) (abbreviated)Sep 7
- Material event report (convertible bonds)
HLB disclosed convertible bonds to raise US$21.1M, about 0.5% of its market value.
Capital raise · Aug 5 - Material event report (convertible bonds)
HLB disclosed convertible bonds to raise US$16.7M, about 0.4% of its market value.
Capital raise · Apr 7 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Mar 9
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
HLB reported consolidated results for FY2025: revenue of US$58.8M (+23.17% year on year), an operating loss of US$75M and a net loss of US$169M.
Earnings · Feb 26